ArticleGland surgery2026
Diagnostic performance of multimodal ultrasonography for molecular subtyping of breast cancer: a retrospective study.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer molecular subtypes differ substantially in treatment selection, therapeutic response, and prognosis, making accurate subtype identification essential for individualized management. Current molecular subtyping mainly relies on immunohistochemical and molecular pathological analyses of biopsy or surgical specimens, which are invasive and may be affected by sampling bias, intratumoral heterogeneity, and testing turnaround time. This study aimed to evaluate the diagnostic performance of multimodal ultrasonography for noninvasive molecular subtyping of breast cancer. Methods: A total of 155 patients diagnosed with breast cancer were retrospectively enrolled. According to molecular classification, patients were categorized into the human epidermal growth factor receptor 2 (HER2)-overexpression subtype (n=32), triple-negative subtype (n=31), luminal A subtype (n=26), and luminal B subtype (n=66). Differences in multimodal ultrasound features among the various molecular subtypes were compared, and the predictive value of multimodal ultrasound parameters for molecular classification was analyzed. Results: Higher maximum elastic modulus (E Conclusions: The molecular subtypes of breast cancer exhibited distinct multimodal ultrasonographic characteristics. Multimodal ultrasonography showed potential value for noninvasive prediction of breast cancer molecular subtypes and may provide auxiliary information for individualized therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.